-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Short Interest in Bright Minds Biosciences Inc. (NASDAQ:DRUG) Decreases By 11.6%
Short Interest in Bright Minds Biosciences Inc. (NASDAQ:DRUG) Decreases By 11.6%
Bright Minds Biosciences Inc. (NASDAQ:DRUG – Get Rating) was the target of a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 824,900 shares, a decline of 11.6% from the November 15th total of 932,900 shares. Currently, 11.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,430,000 shares, the short-interest ratio is presently 0.6 days.
Institutional Investors Weigh In On Bright Minds Biosciences
A hedge fund recently bought a new stake in Bright Minds Biosciences stock. Jane Street Group LLC acquired a new stake in shares of Bright Minds Biosciences Inc. (NASDAQ:DRUG – Get Rating) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 24,701 shares of the company's stock, valued at approximately $37,000. Jane Street Group LLC owned approximately 0.21% of Bright Minds Biosciences at the end of the most recent reporting period. Institutional investors own 4.03% of the company's stock.
Get Bright Minds Biosciences alerts:Bright Minds Biosciences Trading Down 3.2 %
Shares of DRUG stock opened at $0.91 on Tuesday. The stock has a 50 day simple moving average of $1.01 and a 200 day simple moving average of $1.14. Bright Minds Biosciences has a 1 year low of $0.75 and a 1 year high of $4.75.
About Bright Minds Biosciences
(Get Rating)Bright Minds Biosciences Inc, a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry.
Featured Stories
- Get a free copy of the StockNews.com research report on Bright Minds Biosciences (DRUG)
- Will Tesla Shares Rally If Musk Steps Down From Twitter?
- 5 Down But Not Out Stocks To Watch For 2023
- Can Chewy Fetch Double Digit Gains in 2023?
- Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
- Madrigal Pharmaceuticals Stock Is Up 200% In One Day, Here's Why
Receive News & Ratings for Bright Minds Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bright Minds Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
Bright Minds Biosciences Inc. (NASDAQ:DRUG – Get Rating) was the target of a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 824,900 shares, a decline of 11.6% from the November 15th total of 932,900 shares. Currently, 11.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,430,000 shares, the short-interest ratio is presently 0.6 days.
光明之心生物科学公司(纳斯达克:毒品获得评级)是空头股数11月份大幅下跌的目标。截至11月30日,空头股数共有824,900股,较11月15日的932,900股下降11.6%。目前,该股11.0%的股份被卖空。以日均成交量1,430,000股计算,目前短息比率为0.6天。
Institutional Investors Weigh In On Bright Minds Biosciences
机构投资者看好Bright Minds生物科学
A hedge fund recently bought a new stake in Bright Minds Biosciences stock. Jane Street Group LLC acquired a new stake in shares of Bright Minds Biosciences Inc. (NASDAQ:DRUG – Get Rating) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 24,701 shares of the company's stock, valued at approximately $37,000. Jane Street Group LLC owned approximately 0.21% of Bright Minds Biosciences at the end of the most recent reporting period. Institutional investors own 4.03% of the company's stock.
一家对冲基金最近购买了Bright Minds Biosciences股票的新股份。简街集团有限公司(Jane Street Group LLC)根据其最近提交给美国证券交易委员会(SEC)的13F文件,在第一季度收购了光明心灵生物科学公司(Bright Minds Biosciences Inc.)(纳斯达克代码:Drug-Get Rating)的新股。该基金购买了24,701股该公司的股票,价值约37,000美元。在最近一次报告期结束时,简街集团拥有Bright Minds Biosciences约0.21%的股份。机构投资者持有该公司4.03%的股份。
Bright Minds Biosciences Trading Down 3.2 %
光明之心生物科学公司股价下跌3.2%
Shares of DRUG stock opened at $0.91 on Tuesday. The stock has a 50 day simple moving average of $1.01 and a 200 day simple moving average of $1.14. Bright Minds Biosciences has a 1 year low of $0.75 and a 1 year high of $4.75.
周二,药品类股开盘报0.91美元。该股的50日简单移动均线切入位为1.01美元,200日简单移动均线切入位为1.14美元。Bright Minds Biosciences的一年低点为0.75美元,一年高位为4.75美元。
About Bright Minds Biosciences
关于Bright Minds生物科学
Bright Minds Biosciences Inc, a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry.
Bright Minds Biosciences Inc是一家临床前生物科学公司,开发5-羟色胺(5-HT)药物,以改善严重和改变生活的疾病患者的生活。该公司的选择性5-羟色胺受体激动剂组合包括5-HT2C、5-HT2A和5-HT2C/A,用于治疗癫痫、疼痛和神经精神病学。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Bright Minds Biosciences (DRUG)
- Will Tesla Shares Rally If Musk Steps Down From Twitter?
- 5 Down But Not Out Stocks To Watch For 2023
- Can Chewy Fetch Double Digit Gains in 2023?
- Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
- Madrigal Pharmaceuticals Stock Is Up 200% In One Day, Here's Why
- 免费获取StockNews.com关于Bright Minds生物科学(药物)的研究报告
- 如果马斯克退出Twitter,特斯拉的股价会上涨吗?
- 2023年值得关注的5个下跌但不是下跌的股票
- Chewy能否在2023年获得两位数的增长?
- 礼来公司预计将实现持久增长,尽管面临眼前的挑战
- Madrigal制药公司的股票在一天内上涨了200%,原因如下
Receive News & Ratings for Bright Minds Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bright Minds Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Bright Minds生物科学日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Bright Minds Biosciences和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧